Management algorithm for genotype 1 hepatitis C virus

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Kim, Arthur Y ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BOCEPREVIR; HYDROCORTISONE; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; VIRUS RNA; ZINC OXIDE;

ALLELE; ANAL COMPLAINT; ANEMIA; ANTIVIRAL THERAPY; ANUS PRURITUS; ARTICLE; DEPRESSION; DRESS SYNDROME; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENOTYPE; HEMORRHOID; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MEDICAL DECISION MAKING; NEUTROPENIA; PRACTICE GUIDELINE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 84880049742     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-24     Document Type: Article

References (44)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-14. (Pubitemid 46780630)
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD: The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012, 156:271-8.
3. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen H L A: Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007, 147:677-84. (Pubitemid 351664462)
4. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-74.
5. Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ: Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison metaanalysis. QJM 2013, 106:153-63.
6. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ: Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-38.
7. Kwo PY, Lawitz EJ, McConeJ, Schiff ER, VierlingJM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-16.
8. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM: Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013, 368:34-44.
9. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B: Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013, 368:45-53.
10. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-44.
11. Yee HS, Chang MF, Pocha C, Lim J, Ross D, Morgan TR, Monto A: Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2012, 107:669-89; quiz 690.
12. Martinot-Peignoux M, Stern C, Maylin S, Ripault M, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A, Cardoso A, Moucari R, Asselah T, Marcellin P: Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010, 51:1122-6.
13. Payne DW, Talalay P: Isolation of novel microbial 3 alpha-, 3 beta-, and 17 beta-hydroxysteroid dehydrogenases. Purification, characterization, and analytical applications of a 17 beta-hydroxysteroid dehydrogenase from an Alcaligenes sp. J Biol Chem 1985, 260:13648-55. (Pubitemid 16233216)
14. Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J: Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009, 50:407-13.
15. Morgan TR, Ghany MG, Kim H, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok A S F: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010, 52:833-44.
16. Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A: Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 33:146-52. (Pubitemid 36793147)
17. McGovern BH, Birch C, Zaman MT, Bica I, Stone D, Quirk JR, Davis B, Zachary K, Basgoz N, Graeme-Cook F, Gandhi RT: Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon. Clin Infect Dis 2007, 45:1386-92. (Pubitemid 351411919)
18. Brau N: Evaluation of the HCV-Infected Patient: The Initial Encounter. Clin Infect Dis 2012.
19. Manning DS, Afdhal NH: Diagnosis and quantitation of fibrosis. Gastroenterology 2008, 134:1670-81. (Pubitemid 351615414)
20. Smith JO, Sterling RK: Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009, 30:557-76.
21. Thompson AJ, McHutchison JG: Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? Hepatology 2012, 56:373-81.
22. Berger CT, Kim AY: IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am 2012, 26:863-77.
23. Kwo PY: Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int 2012, 32(Suppl 1):39-43.
24. Poordad F, Bronowicki J, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR: Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012, 143:608-18. e 1-5.
25. ™ (boceprevir; package insert). Schering Corporation: Whitehouse Station, NJ; 2011.
26. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, Van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M: Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-28.
27. Thompson AJ, Shiffman ML, Rossaro L, Ghalib R, Han SB, Beavers KL, Pianko S, George J, He L, Wu X, et al.: Six weeks of a NS5A inhibitor (GS-5885), protease inhibitor (GS-9451) plus peginterferon/ribavirin (PR) achieves high SVR4 rates in genotype 1 IL28B CC treatment naive HCV patients: interim results of a prospective, randomized trial. Hepatology 2012, 56:556A.
28. Naggie S, Sulkowski MS: Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012, 142:1324-1334.e3.
29. ™ (telaprevir; package insert). Vertex Pharmaceuticals Inc: Cambridge, MA; 2011.
30. Lontok E, Mani N, Harrington PR, Miller V: Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy. Clin Infect Dis 2013, 56:1466-70.
31. Sulkowski MS, Roberts S, Afdhal NH, Andreone P, Diago M, Pol S, Poordad F, Zeuzem S, Bengtsson L, Luo D, et al.: Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies. European Association for the Study of the Liver 47th Annual Meeting; Barcelona, Spain, 2012.
32. Poordad F, Lawitz EJ, Reddy KR, Afdhal NH, Hezode C, Zeuzem S, Lee SS, Calleja JL, Brown RS, Craxi A, et al.: A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. European Association for the Study of the Liver 47th Annual Meeting; Barcelona, Spain, 2012.
33. Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M: Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008, 36:250-5.
34. Roomer R, Hansen BE, Janssen H L A, De Knegt RJ: Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010, 52:1225-31.
35. Sherman KE: Managing adverse effects and complications in completing treatment for hepatitis C virus infection. Top Antivir Med 2012, 20:125-8.
36. Roomer R, Hansen BE, Janssen H L A, De Knegt RJ: Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol 2010, 53:455-9.
37. ® (eltrombopag). [http://www.gsk.com/media/press-releases/2012/ FDA-approves-new-indication-for-PROMACTA-eltrombopag.html]
38. FDA News Release: FDA announces changes to risk strategy requirements for 2 drugs to treat low platelet counts - Nplate (romiplostim) and Promacta (eltrombopag). [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm282502.htm]
39. Incivek (telaprevir) In combination with drugs peginterferon alfa and ribavirin (Incivek combination treatment): drug safety communication - serious skin reactions. [http://www.fda.gov/Safety/MedWatch/Safetylnformation/ SafetyAlertsforHumanMedicalProducts/ucm332860.htm]
40. Carlson A, Gregorich Z, Striker R: Telaprevir to boceprevir switch highlights lack of cross-reactivity. Clin Infect Dis 2013, 56:552-4.
41. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S: Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-16.
42. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P: Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebocontrolled trial. Psychosomatics 2010, 51:401-8.
43. De Knegt RJ, Bezemer G, Van Gool AR, Drenth J P H, Hansen BE, Droogleever Fortuyn HA, Weegink CJ, Hengeveld MW, Janssen H L A: Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011, 34:1306-17.
44. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T: Escitalopram for the prevention of peginterferon-a2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012, 157:94-103.